Gloria Lee, MD, PhD
Dr. Lee has broad expertise in taking products from early clinical development through marketing approval in biotechnology and pharmaceutical organizations. With over 28 years experience developing small molecules into cell-based therapy products, she previously served as Chief Medical Officer at Beyondspring Pharmaceuticals, EVP, Clinical and Medical Affairs at Delcath Systems, and was the first CMO at Kite Pharma. Dr. Lee participated in the Taxotere NDA at Rhone-Poulenc Rorer and registration-enabling clinical development of Zytiga at Cougar Biotechnology. Previous projects included ibandronate at Hoffmann-La Roche, tezacitabine at Chiron, entinostat at Syndax Pharmaceuticals, GM-CSF at Sandoz, P53 gene therapy at Rhone-Poulenc Rorer Gencell and various early-phase biologics and immunotherapy. Dr. Lee received her PhD from Columbia University and MD from University of Miami. She completed her Internal Medicine residency at Georgetown University Hospital and Hematology-Oncology fellowship at Fox Chase Cancer Center.